Navidea Biopharmaceuticals to Co-Sponsor Alzheimer’s Imaging Consortium at Alzheimer’s Association International Conference

  Navidea Biopharmaceuticals to Co-Sponsor Alzheimer’s Imaging Consortium at
  Alzheimer’s Association International Conference

  Educational sessions will focus on clinical application and development of
               neuroimaging to Alzheimer’s disease and dementia

Alzheimer’s Association International Conference

Business Wire

DUBLIN, Ohio -- July 11, 2013

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that it
will co-sponsor the 2013 Alzheimer’s Imaging Consortium on July 13, 2013. The
full-day event features leading international experts and will be chaired by
Drs. Gil Rabinovici, University of California, San Francisco, United States,
and Christopher Rowe, Austin Health, Melbourne, Australia. The Consortium is
part of the Alzheimer’s Association International Conference (AAIC), being
held July 13 – 18, 2013, in Boston, Mass. The annual AAIC is attended by
leaders in dementia research and medicine from around the globe, and is the
largest conference of its kind in the world.

“We are honored that Navidea is supporting the Alzheimer’s Imaging Consortium,
because education and peer-to-peer scientific dialogue are fundamental to
advancing important clinical knowledge that can lead to more informed
diagnosis and improved care for patients with Alzheimer’s disease and other
dementias,” said Dr. Connie Reininger, Navidea’s Senior Vice President and
Chief Medical Officer.

“Navidea’s commitment to advancing precision diagnostics encompasses our
neuroimaging candidates NAV4694, in development for use as an aid in the
diagnosis of Alzheimer’s disease and potentially Mild Cognitive Impairment;
and NAV5001, which we are developing to aid in the evaluation of patients who
may have dementia with Lewy Bodies, in addition to its benefits in the
diagnosis of Parkinson’s Disease,” commented Dr. Mark Pykett, Chief Executive
Officer of Navidea.

The Alzheimer's Imaging Consortium will consist of invited speakers, as well
as oral and poster presentations from submitted abstracts. Leading imaging and
non-imaging researchers from around the world will discuss topics such as:

  *Early and differential diagnosis and the proposal for new criteria;
  *Tracking progression and evaluating treatments;
  *Asymptomatic stages of Alzheimer's and normal brain aging;
  *Cognitive and basic neuroscientific studies: animal imaging, imaging and
  *Multi-modality imaging studies and new imaging methods; and
  *The latest developments on other dementias such as Lewy body disease and
    vascular diseases.

About NAV4694

NAV4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate
intended for use in Positron Emission Tomography (PET) imaging and evaluation
of patients with signs or symptoms of cognitive impairment such as Alzheimer’s
disease (AD). NAV4694 binds to β-amyloid deposits in the brain that can then
be imaged in scans. β-amyloid plaque pathology is widely used in the diagnosis
of AD. The ability of NAV4694 imaging to display amyloid plaque pathology may
enable earlier identification of AD and improve monitoring of disease
progression and interpretation of brain scan images. Navidea has an ongoing
NAV4694 Phase 2b trial in Mild Cognitive Impairment and a Phase 3 program for
NAV4694 in AD.

About Alzheimer’s

Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disease
which affects a person’s memory and ability to learn, reason, communicate and
carry out daily activities. Increasing age is the greatest risk factor for AD
and there is no prevention or cure. The World Health Organization estimates
that Alzheimer’s disease affects over 24 million people worldwide. Currently
in the U.S. alone, there are over 5 million Alzheimer’s patients with
estimates that by 2050, as many as 14 million Americans could have the disease
according to the Alzheimer’s Association. Among the brain changes believed to
contribute to the development of Alzheimer’s are the accumulation of the
protein β-amyloid outside nerve cells (neurons) in the brain and the
accumulation of the protein tau inside neurons. Approximately 75 to 100
experimental technologies aimed at diagnosing, slowing or stopping the
progression of Alzheimer’s are now in human clinical trials.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe
harbor for forward-looking statements made by or on behalf of the Company.
Statements in this news release, which relate to other than strictly
historical facts, such as statements about the Company’s plans and strategies,
expectations for future financial performance, new and existing products and
technologies, anticipated clinical and regulatory pathways, and markets for
the Company’s products are forward-looking statements within the meaning of
the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,”
and similar expressions identify forward-looking statements that speak only as
of the date hereof. Investors are cautioned that such statements involve risks
and uncertainties that could cause actual results to differ materially from
historical or anticipated results due to many factors including, but not
limited to, the Company’s continuing operating losses, uncertainty of market
acceptance of its products, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on
limited product line and distribution channels, competition, limited marketing
and manufacturing experience, risks of development of new products, regulatory
risks and other risks detailed in the Company’s most recent Annual Report on
Form 10-K and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any forward-looking


Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200
Press spacebar to pause and continue. Press esc to stop.